# Techcyte and Evident Expand Partnership With Flexible Business Models for Digital Pathology > Techcyte and Evident expanded their partnership to offer flexible acquisition options for end-to-end digital pathology, pairing Pramana scanners. - Published: 2026-10-17T18:33:53+00:00 - Section: Partnerships - Author: News Desk - URL: https://newsforagent.com/news/2026-10-17/techcyte-evident-digital-pathology-partnership - Source: [EIN Presswire](https://www.einnews.com/pr_news/950272270/techcyte-and-evident-expand-partnership-with-flexible-business-models-for-end-to-end-digital-pathology) ## Key takeaways - Techcyte and Evident expanded a partnership that pairs Evident's Pramana whole-slide scanners with Techcyte's Fusion platform. - The collaboration extends digital pathology beyond histology to cytology, hematology, microbiology and parasitology. - Techcyte closed a $15 million capital raise in April 2026 led by Van Tuyl Companies with participation from Zoetis and Mayo Clinic. [Techcyte](https://akta.pro/company-profiles/00007be/techcyte) and [Evident](https://akta.pro/company-profiles/00058hk/evident-corporation) expanded their partnership to offer flexible business models for end-to-end digital pathology, combining Evident's Pramana whole-slide scanners with Techcyte's Fusion platform. [EIN Presswire](https://www.einnews.com/pr_news/950272270/techcyte-and-evident-expand-partnership-with-flexible-business-models-for-end-to-end-digital-pathology) published the announcement on October 17, 2026. Customers can choose how they acquire the technology, and the collaboration extends digital pathology beyond histology to cytology, hematology, microbiology and parasitology. ## How the Techcyte and Evident Partnership Works Techcyte and Evident have worked together for several years, from autonomous imaging with Evident's Pramana whole-slide scanners to case handling and reporting with Techcyte Fusion. The two companies said the collaboration spans many applications and extends digital pathology beyond histology to cytology, hematology, microbiology and parasitology. "Our work with Evident has always been about making digital pathology simpler for labs, from the scanner to the final report," said Ben Cahoon, CEO of Techcyte. "Aligning our business models takes that step further. Customers can now choose how they acquire the technology and get the scanner, enterprise digital pathology software, and AI from two teams that have a proven track record of innovating together." Prasanth Perugupalli, Vice President of Digital Pathology at Evident Scientific, said Evident's Pramana scanners and the Techcyte Fusion platform are used together to support a growing range of lab workflows in the US and Europe. He said the modular architecture and quality assured imaging offered by the Pramana scanners made it possible to innovate on business models with Techcyte, including scaling capacity on demand and removing additional hidden costs in operations. Evident announced the Pramana POD benchtop whole slide imaging scanner at Pathology Visions 2026, designed for small and medium-sized laboratories, according to PR Newswire. The system automates imaging with tissue finder, label detection and volumetric imaging, delivering true 40X at 25 slides per hour. Techcyte Fusion and Evident's Pramana scanners are for Research Use Only in the United States. Techcyte and Evident will exhibit at Pathology Visions 2026, held October 16 to 18 in San Diego, at booth #410 and booth #106 respectively. ## Techcyte's Funding and Platform Scale According to akta.pro [company records](https://akta.pro/company-data), Techcyte closed a $15 million capital raise in April 2026 led by Van Tuyl Companies with participation from existing investors Zoetis and Mayo Clinic, providing access to Mayo Clinic's Safe Harbor dataset of more than 17 million de-identified slides for AI training. The same records show Techcyte achieved CE marking under the European In Vitro Diagnostic Regulation (EU) 2017/746 for the Fusion AP digital pathology platform in March 2026, enabling commercialization across the European Economic Area. Techcyte analyzed nearly 9 million digital scans across all platforms in 2025, against more than 3 million in 2024. ## Earlier Techcyte Platform Integrations Techcyte and Aignostics launched an AI-guided macrodissection workflow for next-generation sequencing on Techcyte Fusion AP in October 2026, using Aignostics' HETA Tumor Cellularity, EIN Presswire reported. Pictor Labs' ClearStain virtual H&E became available in Techcyte Fusion AP in October 2026, allowing pathologists to annotate unstained tissue sections for molecular extraction, EIN Presswire reported. NovoPath and Techcyte announced an integration between the NovoPath LIS and Techcyte Fusion in October 2026, linking whole-slide images and AI analysis to NovoPath LIS cases, EIN Presswire reported. ## Pathology Visions 2026 Dates Techcyte and Evident will exhibit at Pathology Visions 2026, held October 16 to 18 in San Diego. Techcyte will be at booth #410 and Evident at booth #106. ## Companies in this story - [Techcyte company profile](https://akta.pro/company-profiles/00007be/techcyte) · website: https://www.techcyte.com - [Evident Corporation company profile](https://akta.pro/company-profiles/00058hk/evident-corporation) · website: https://www.evidentscientific.com --- News for Agent · https://newsforagent.com/llms.txt